If the nominal theme of Windhover's 2004 Pharmaceutical Strategic Alliances conference was "transitions", the full subtext was "transitions to sustainability." Mid-sized players appear to have the best shot at sustainability in an environment where, increasingly, less differentiated, primary care blockbusters are out, and specialist products are in.
If the nominal theme of Windhover's 2004 Pharmaceutical
Strategic Alliances conference was "transitions", the full
subtext was "transitions to sustainability."
Sustainability would hardly seem to be a matter of much dispute when it comes to Big Pharma. But serious threats...